Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cancer cells display a variety of global metabolic changes, which aside from the glycolytic pathway largely involve amino acid metabolism. To ensure aggressive growth, tumor cells highly depend on amino acids, most notably due to their pivotal need of protein synthesis. In this study, we assessed the overall hypothesis that depletion of asparagine by E. coli-derived
L-asparaginase
might be a novel means for the therapy of one of the most recalcitrant neoplasms and for which no efficient treatment currently exists -
glioblastoma
(WHO grade IV). Our results suggest that certain glioma cell cultures are particularly susceptible to inhibition of proliferation by
L-asparaginase
, while others display a more resistant phenotype. In sensitive cells,
L-asparaginase
induces apoptosis with dissipation of mitochondrial membrane potential and activation of effector caspases.
L-asparaginase
-mediated apoptosis was accompanied by modulation of pro- and anti-apoptotic Bcl-2 family members, including Noxa, Mcl-1 and the deubiquitinase Usp9X. Given the impact of
L-asparaginase
on these molecules, we found that
L-asparaginase
potently overcomes resistance to both intrinsic apoptosis induced by the Bcl-2/Bcl-xL inhibitor, ABT263, and extrinsic apoptosis mediated by TRAIL even in glioma cells that are resistant towards
L-asparaginase
single treatment. RNA interference studies showed that Usp9X, Mcl-1, Noxa and Bax/Bak are involved in ABT263/
L-asparaginase
-mediated cell death. In vivo, combined treatment with ABT263 and
L-asparaginase
led to an enhanced reduction of tumor growth when compared to each reagent alone without induction of toxicity. These observations suggest that
L-asparaginase
might be useful for the treatment of malignant glial neoplasms.
...
PMID:Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. 2717 99
Asparaginase has been reported to be effective in the treatment of various leukemia and several malignant solid cancers. However, the anti-tumor effect of
asparaginase
is always restricted due to complicated mechanisms. Herein, we investigated the mechanisms of how
glioblastoma
resisted
asparaginase
treatment and reported a novel approach to enhance the anti-
glioblastoma
effect of
asparaginase
. We found that
asparaginase
could induce growth inhibition and caspase-dependent apoptosis in U87MG/U251MG
glioblastoma
cells. Meanwhile, autophagy was activated as indicated by autophagosomes formation and upregulated expression of LC3-II. Importantly, abolishing autophagy using chloroquine (CQ) and LY294002 enhanced the cytotoxicity and apoptosis induced by
asparaginase
in U87MG/U251MG cells. Further study proved that Akt/mTOR and Erk signaling pathways participated in autophagy induction, while reactive oxygen species (ROS) served as an intracellular regulator for both cytotoxicity and autophagy in
asparaginase
-treated U87MG/U251MG cells. Moreover, combination treatment with autophagy inhibitor CQ significantly enhanced anti-
glioblastoma
efficacy of
asparaginase
in U87MG cell xenograft model. Taken together, our results demonstrated that inhibition of autophagy potentiated the anti-tumor effect of asparagine depletion on
glioblastoma
, indicating that targeting autophagy and asparagine could be a potential approach for
glioblastoma
treatment.
...
PMID:Autophagy suppression potentiates the anti-glioblastoma effect of asparaginase
in vitro
and
in vivo
. 2920 24